ACAD
ACADIA Pharmaceuticals Inc
NASDAQ: ACAD · HEALTHCARE · BIOTECHNOLOGY
$21.80
-0.74% today
Updated 2026-06-05
Market cap
$3.61B
P/E ratio
9.54
P/S ratio
3.30x
EPS (TTM)
$2.21
Dividend yield
—
52W range
$20 – $28
Volume
1.7M
ACADIA Pharmaceuticals Inc (ACAD) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$21.80
12-Month target
$21.13
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.5B | $0.5B | $0.7B | $1.0B | $1.1B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 9.54x (capped 25x) · Margin: 34.30%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.